- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Patent holdings for IPC class A61K 38/47
Total number of patents in this class: 2332
10-year publication summary
|
173
|
173
|
193
|
200
|
209
|
248
|
201
|
162
|
186
|
121
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Halozyme, Inc. | 171 |
87 |
| Amicus Therapeutics, Inc. | 354 |
72 |
| Translate bio, Inc. | 415 |
45 |
| Janssen Biotech, Inc. | 1768 |
44 |
| Curemark, LLC | 79 |
40 |
| Novozymes A/S | 3383 |
36 |
| The Regents of the University of California | 20790 |
35 |
| Genzyme Corporation | 1370 |
30 |
| Duke University | 3183 |
29 |
| The Trustees of the University of Pennsylvania | 4416 |
28 |
| Takeda Pharmaceutical Company Limited | 2713 |
27 |
| DSM IP Assets B.V. | 5377 |
19 |
| Regeneron Pharmaceuticals, Inc. | 4741 |
19 |
| Universitat Autonoma de Barcelona | 337 |
19 |
| Ansun Biopharma, Inc. | 46 |
17 |
| Genentech, Inc. | 4113 |
16 |
| Massachusetts Institute of Technology | 10259 |
16 |
| BioMarin Pharmaceutical Inc. | 398 |
16 |
| The Rockefeller University | 584 |
16 |
| ContraFect Corporation | 56 |
16 |
| Other owners | 1705 |